根据 LASSO 筛选出的非肌层浸润性膀胱癌术前炎症和营养标记物得出的预后指数

IF 2.3 3区 医学 Q3 ONCOLOGY Clinical genitourinary cancer Pub Date : 2024-06-01 DOI:10.1016/j.clgc.2024.02.012
Dengxiong Li , Ruicheng Wu , Jie Wang , Junjiang Ye , Qingxin Yu , Dechao Feng , Ping Han
{"title":"根据 LASSO 筛选出的非肌层浸润性膀胱癌术前炎症和营养标记物得出的预后指数","authors":"Dengxiong Li ,&nbsp;Ruicheng Wu ,&nbsp;Jie Wang ,&nbsp;Junjiang Ye ,&nbsp;Qingxin Yu ,&nbsp;Dechao Feng ,&nbsp;Ping Han","doi":"10.1016/j.clgc.2024.02.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>There is an urgent need to identify a robust predictor for BCG response in patients with non–muscle-invasive bladder cancer (NMIBC). We aimed to employ the Lasso regression model for the selection and construction of an index (BCGI) utilizing inflammation and nutrition indicators to predict the response to BCG therapy.</p></div><div><h3>Methods</h3><p>After acquiring the ethics approval, we searched the electric medical records in our institution and performed data screening. Then, we developed the BCGI using a Lasso regression model and subsequently evaluated its performance in both the train and internal test datasets through Kaplan-Meier survival curves and Cox regression analysis. Then, we also evaluated the prognostic value of BCGI alongside the EAU2021 model.</p></div><div><h3>Results</h3><p>The training dataset and internal test dataset contained 295 and 196 patients, respectively. Referring to the Lasso results, BCGI consisted of hemoglobin, albumin, and platelet count, which could significantly predict the recurrence of NMIBC patients who accepted BCG in train (<em>P</em> = .012) and test (<em>P</em> = .004) datasets. The BCGI also exhibited statistically prognostic value in no smoking history, World Health Organization high grade, and T1 subgroups, both in train and test datasets. In multivariable analysis, BCGI exhibited independent prognostic value in train (<em>P</em> = .012) and test (<em>P</em> = .012) datasets. Finally, we constructed a nomogram that consisted of smoking history, T stage, World Health Organization grade, tumor size, and BCGI. Then, BCGI demonstrated significant independent prognostic value in NMIBC patients treated with BCG, a result not observed with the EAU2021 score or classification.</p></div><div><h3>Conclusion</h3><p>Based on the results, we reasonably suggest that BCGI may be a useful predictor for NMIBC patients who accepted BCG. Furthermore, we have demonstrated the efficacy of constructing a prognostic index using clinical factors and a Lasso regression model, a versatile approach applicable to various medical conditions.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non–Muscle-Invasive Bladder Cancer\",\"authors\":\"Dengxiong Li ,&nbsp;Ruicheng Wu ,&nbsp;Jie Wang ,&nbsp;Junjiang Ye ,&nbsp;Qingxin Yu ,&nbsp;Dechao Feng ,&nbsp;Ping Han\",\"doi\":\"10.1016/j.clgc.2024.02.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>There is an urgent need to identify a robust predictor for BCG response in patients with non–muscle-invasive bladder cancer (NMIBC). We aimed to employ the Lasso regression model for the selection and construction of an index (BCGI) utilizing inflammation and nutrition indicators to predict the response to BCG therapy.</p></div><div><h3>Methods</h3><p>After acquiring the ethics approval, we searched the electric medical records in our institution and performed data screening. Then, we developed the BCGI using a Lasso regression model and subsequently evaluated its performance in both the train and internal test datasets through Kaplan-Meier survival curves and Cox regression analysis. Then, we also evaluated the prognostic value of BCGI alongside the EAU2021 model.</p></div><div><h3>Results</h3><p>The training dataset and internal test dataset contained 295 and 196 patients, respectively. Referring to the Lasso results, BCGI consisted of hemoglobin, albumin, and platelet count, which could significantly predict the recurrence of NMIBC patients who accepted BCG in train (<em>P</em> = .012) and test (<em>P</em> = .004) datasets. The BCGI also exhibited statistically prognostic value in no smoking history, World Health Organization high grade, and T1 subgroups, both in train and test datasets. In multivariable analysis, BCGI exhibited independent prognostic value in train (<em>P</em> = .012) and test (<em>P</em> = .012) datasets. Finally, we constructed a nomogram that consisted of smoking history, T stage, World Health Organization grade, tumor size, and BCGI. Then, BCGI demonstrated significant independent prognostic value in NMIBC patients treated with BCG, a result not observed with the EAU2021 score or classification.</p></div><div><h3>Conclusion</h3><p>Based on the results, we reasonably suggest that BCGI may be a useful predictor for NMIBC patients who accepted BCG. Furthermore, we have demonstrated the efficacy of constructing a prognostic index using clinical factors and a Lasso regression model, a versatile approach applicable to various medical conditions.</p></div>\",\"PeriodicalId\":10380,\"journal\":{\"name\":\"Clinical genitourinary cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical genitourinary cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S155876732400034X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S155876732400034X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

非肌层浸润性膀胱癌(NMIBC)患者对卡介苗(Bacillus Calmette-Guerin,BCG)治疗反应的预测亟需一个可靠的指标。在获得伦理批准后,我们检索了本机构的电子病历并进行了数据筛选。然后,我们利用 Lasso 回归模型开发了卡介苗指数,随后通过 Kaplan-Meier 生存曲线和 Cox 回归分析评估了卡介苗指数在训练数据集和内部测试数据集中的表现。然后,我们还评估了 BCGI 与 EAU2021 模型的预后价值。训练数据集和内部测试数据集分别包含 295 名和 196 名患者。根据Lasso结果,BCGI由血红蛋白、白蛋白和血小板计数组成,在训练数据集(P=0.012)和测试数据集(P=0.004)中可显著预测接受卡介苗治疗的NMIBC患者的复发情况。在训练数据集和测试数据集中,BCGI在无吸烟史、WHO高级别和T1亚组中也显示出统计学预后价值。在多变量分析中,BCGI 在训练数据集(P=0.012)和测试数据集(P=0.012)中均显示出独立的预后价值。最后,我们构建了一个由吸烟史、T分期、WHO分级、肿瘤大小和BCGI组成的提名图。然后,BCGI 在接受卡介苗治疗的 NMIBC 患者中显示出显著的独立预后价值,而 EAU2021 评分或分级均未观察到这一结果。基于上述结果,我们合理地认为,BCGI 可能是预测接受卡介苗治疗的 NMIBC 患者预后的有效指标。此外,我们还证明了利用临床因素和拉索回归模型构建预后指数的有效性,这是一种适用于各种医疗条件的通用方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non–Muscle-Invasive Bladder Cancer

Background

There is an urgent need to identify a robust predictor for BCG response in patients with non–muscle-invasive bladder cancer (NMIBC). We aimed to employ the Lasso regression model for the selection and construction of an index (BCGI) utilizing inflammation and nutrition indicators to predict the response to BCG therapy.

Methods

After acquiring the ethics approval, we searched the electric medical records in our institution and performed data screening. Then, we developed the BCGI using a Lasso regression model and subsequently evaluated its performance in both the train and internal test datasets through Kaplan-Meier survival curves and Cox regression analysis. Then, we also evaluated the prognostic value of BCGI alongside the EAU2021 model.

Results

The training dataset and internal test dataset contained 295 and 196 patients, respectively. Referring to the Lasso results, BCGI consisted of hemoglobin, albumin, and platelet count, which could significantly predict the recurrence of NMIBC patients who accepted BCG in train (P = .012) and test (P = .004) datasets. The BCGI also exhibited statistically prognostic value in no smoking history, World Health Organization high grade, and T1 subgroups, both in train and test datasets. In multivariable analysis, BCGI exhibited independent prognostic value in train (P = .012) and test (P = .012) datasets. Finally, we constructed a nomogram that consisted of smoking history, T stage, World Health Organization grade, tumor size, and BCGI. Then, BCGI demonstrated significant independent prognostic value in NMIBC patients treated with BCG, a result not observed with the EAU2021 score or classification.

Conclusion

Based on the results, we reasonably suggest that BCGI may be a useful predictor for NMIBC patients who accepted BCG. Furthermore, we have demonstrated the efficacy of constructing a prognostic index using clinical factors and a Lasso regression model, a versatile approach applicable to various medical conditions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical genitourinary cancer
Clinical genitourinary cancer 医学-泌尿学与肾脏学
CiteScore
5.20
自引率
6.20%
发文量
201
审稿时长
54 days
期刊介绍: Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
期刊最新文献
Survival Outcomes by Race Following Surgical Treatment for Upper Tract Urothelial Carcinoma Adverse Health Outcomes 3 Years after Radical Prostatectomy Compared with Men in the General Population: A Study from the Cancer Registry of Norway Outcomes of Radical Radiotherapy for the Treatment of Localized Renal Pelvic and Ureteral Carcinoma Intolerant to Surgery: A Real-World Study Roles of Long Noncoding RNA in Prostate Cancer Pathogenesis Markers in Identifying Pathological Complete Response Status in Muscle Invasive Bladder Cancer Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1